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In South Africa (SA), colorectal cancer (CRC) is the fourth most 
common cancer among both men and women. The crude incidence 
is 7.17/100 000/year for men and 5.80/100 000/year for women,[1] and 
CRC ranks sixth in cancer-related mortality.[2]
The cumulative lifetime risk of developing CRC in SA is 1.24 for 
males and 0.74 for females.[1] At the time of CRC diagnosis, 20 - 25% 
of patients will have metastatic disease,[3] the liver being the most 
common site.[4] More than half of the patients who undergo curative 
resection may expect to have tumour recurrence, either locally 
or as metastatic disease.[5] CRC therefore represents a significant 
healthcare burden.
Five-year overall survival rates for CRC are 93.2% for stage I, 72.2 - 
84.7% for stage II, 52.3 - 83.4% for stage III and 8.1% for stage IV. [6] 
Stage IV disease treated with chemotherapy alone has a median 
overall survival of 12 months.[7] Various treatment algorithms have 
been incorporated into international guidelines, but common to most 
is that, when possible, surgical resection of the primary lesion and 
its metastases offers the best survival benefit for patients.[8] So far, 
a specific treatment algorithm tailored to SA patients has not been 
published.
Objectives
To describe the presentation of CRC patients in a privately insured 
population in SA, general clinical management trends, and 5-year 
overall survival for various disease stages.
Methods
Study design and data collection
A retrospective review of a private healthcare funder’s database 
from 1 January 2008 to 31 December 2015 was undertaken. Ethics 
approval was granted by the University of the Witwatersrand Human 
Research Ethics Committee (ref. no. M141027), and consent to 
obtain deidentified data was given by the principal officer of the 
private healthcare funder. The initial dataset was based on claims by 
and clinical information on active members of the medical scheme. 
Data were extracted from tables developed by the medical scheme 
for analysis where the table development included data validation. 
Unique entities were identified from these data tables of members 
with a validated CRC diagnosis.
Patients included in this study were enrolled on the scheme’s 
oncology benefit for the treatment of CRC. International Statistical 
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Background. Colorectal cancer (CRC) is the fourth most common cancer in South Africa (SA), and the sixth most lethal. Approximately 
25% of patients will have synchronous metastatic disease at the time of their primary CRC diagnosis. Although chemotherapy is used in 
most stages of the disease, surgical resection of the primary tumour and metastases remains the most successful treatment modality to 
achieve cure or prolong survival. To date, no data on CRC presentation and management have been published in SA.
Objectives. To determine CRC presentation, general management patterns and overall survival in the SA private healthcare sector.
Methods. A retrospective review of a private healthcare funder’s database from 1 January 2008 to 31 December 2015. International Statistical 
Classification of Diseases and Related Health Problems (10th revision) (ICD-10) diagnosis codes were used to identify colorectal cancer and 
liver and/or pulmonary metastatic disease. Procedure codes assigned to hospital admissions were used to identify type of surgical treatment. 
Chemotherapy was identified by the World Health Organization Anatomical Therapeutic Chemical Classification System of medicines. 
Treatment patterns were determined and 5-year survival rates for these were calculated. Survival was estimated using the Kaplan-Meier 
method, and Cox proportional hazards regression was used for between-group comparisons of survival. Data analysis was carried out using 
SAS version 9.4 for Windows.
Results. A total of 3 412 patients were included in the study, 2 267 with CRC only and 1 145 with liver (LM) or pulmonary metastases 
(PM). The mean age was 64.1 years (range 21 - 97), and 54.6% were male; these did not differ statistically between the study groups. Twenty 
percent of patients with LM or PM underwent surgical resection of their metastases. Five-year survival rates following surgical resection of 
all disease for CRC only, CRCLM, CRCPM and CRCLMPM were 71.7%, 57.3%, 31.5% and 26.0%, respectively.
Conclusions. SA CRC patients treated in the private healthcare sector have similar disease presentation to that in published international 
series, with similar outcomes following various treatment pathways; however, it seems that fewer resections of metastases are undertaken 
compared with international trends.
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Classification of Diseases and Related Health Problems (10th revision) 
(ICD-10) diagnosis codes were used to identify CRC only, with or 
without liver and/or pulmonary metastatic disease. Once identified, 
secondary or unspecified malignant neoplasms of the digestive organs 
or respiratory tract were sought for in this patient population. The 
authors examined each identified record to determine whether or not 
the additional diagnosis was relevant to the initial CRC diagnosis. Sites 
of metastases other than the liver and lungs were excluded.
All procedure codes assigned to hospital admissions were captured, 
and each code was examined by the authors to identify surgical 
treatments relevant to resections of CRC and CRC metastases. All 
other procedures were excluded. Chemotherapy was identified by 
the World Health Organization Anatomical Therapeutic Chemical 
Classification System of medicines. The number of days from 
diagnosis of CRC and/or CRC metastases and from surgical resection 
were collected. Death was based on date of withdrawal from the 
medical scheme, and survival on ongoing contribution to the 
scheme. Patients were excluded if they were aged <18 years or were 
diagnosed before 1 January 2008, and if they were diagnosed on or 
after 1  January 2014 to ensure that we did not miss any treatment 
modalities and that patients had at least 1 year of follow-up.
Each patient’s treatment was assessed as surgical resection of the 
cancer with or without chemotherapy, chemotherapy without surgical 
resection, or no treatment (no surgical resection or chemotherapy). 
Four patient groups were used for analysis: (i) CRC only; (ii) 
CRC and liver metastases (CRCLM); (iii) CRC and pulmonary 
metastases (CRCPM); and (iv) CRC, liver and pulmonary metastases 
(CRCLMPM).
Statistical analysis
Crude incidence was calculated and represented as 100 000/
year. Categorical variables were summarised as percentages, and 
continuous variables were summarised as means, standard deviations 
(SDs), medians and interquartile ranges. Survival was estimated using 
the Kaplan-Meier method and Cox proportional hazards regression 
was used for between-group comparisons of survival. The 5% 
significance level was used. Data analysis was carried out using SAS 
version 9.4 for Windows (SAS Institute, USA).
Results
A total of 3 412 patients were included in the study (Fig. 1). Their 
demographic features are set out in Table 1. The total number of 
members on 1 January 2015 was 2 658 100, with 5 093 diagnosed 
with CRC. The crude incidence of CRC in this insured population 
increased from 18.9/100 000 in 2008 to 21.3/100 000 in 2015. The 
gender composition for each patient group was similar, apart from 
the proportion of males being significantly higher in the CRCLM 
group compared with the CRC-only group (p=0.037) (Table 1). 
The mean age of the CRC-only group (64.1 years, SD 12.8) was 
significantly higher than that of the CRCLMPM group (61.5 years, 
SD 11.7) (p<0.0001). There was no statistically significant difference 
between the CRCLM, CRCPM and CRCLMPM groups (Table 1).
Disease presentation, proportions of cancer with or without meta-
stases, and management pathways of the study group are presented 
in Fig. 2. One-third of patients either presented with or developed 
LM and/or PM, the most common being LM. Two-thirds of these 
patients underwent surgical resection, but only 7.2% (83/1 145) of 
patients with metastatic disease underwent meta statectomy. The 
most common was resection of LM, but only 10.0% (60/601) of 
patients with LM underwent liver resection; of these, 6.7% (4/60) 
underwent more than one liver resection. Of patients with CRC 
only, the majority underwent resection of their primary lesion. No 
treatment was recorded by the medical aid scheme for 16.5% of 
patients.
Fig. 3 depicts overall survival regardless of therapy. Using the CRC-
only group as reference, the risk of death was higher for all the other 
three cancer groups, and highest for CRCLMPM. Five-year overall 
survival (5YOS) for CRCPM was better than for CRCLM.
Table 2 describes treatment-related 5-year survival. The best 
5YOS was for CRC without metastatic disease treated by surgical 
resection and chemotherapy. For patients with metastatic disease, 
CRCLM resection preceded by chemotherapy provided the best 
5YOS of 40.7%. CRCPM resection with chemotherapy had 5YOS of 
31.7%. There were 5-year overall survivors who did not have surgical 
Whole data set,
N=5 093
CRC diagnosis before 1 Jan 2008 excluded
n=3 913
CRC diagnosis after 31 Dec 2014 excluded
n=3 414
Patients aged <18 years excluded
n=3 412
Fig. 1. Data selection, 1 January 2008 - 31 December 2015. (CRC = colo-
rectal cancer.)
Table 1. Overview of CRC patients
All cases CRC only CRCLM CRCPM CRCLMPM
Survival, n (%) 3 412 2 267 (66.4) 601 (17.6) 182 (5.3) 362 (10.6)
Age (yr), mean (range) 64.1 (21 - 97) 64.7 (21 - 97) 63.6 (25 - 93) 62.6 (23 - 85) 61.5 (23 - 87)
Gender, n (%)
Males 1 862 (54.6) 1 203 (53.1) 357 (59.4) 97 (53.3) 205 (56.6)
Females 1 550 (45.4) 1 064 (46.9) 244 (40.6) 85 (46.7) 157 (43.4)
CRC = colorectal cancer; LM = liver metastases; PM = pulmonary metastases.
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resection of metastases, but the figure was significantly lower than if 
they had had all their disease resected.
Discussion
This is the first study to determine survival outcomes of CRC with or 
without LM and/or PM in a selected, privately insured SA population. 
We have demonstrated that one-third of patients with CRC present 
with or develop LM and/or PM, of whom 7% undergo surgical 
metastatectomy. 5YOS is best for patients with disease isolated to 
the colon or rectum that is resected and treated with chemotherapy. 
Furthermore, there is improved survival with surgical resection in 
combination with chemotherapy of LM and/or PM.
Incidence and presentation of CRC
The global incidence rates of CRC, overall and in males and females, 
are 17.2/100 000, 20.6/100 000 and 14.3/100 000, respectively. The 
incidence rates of CRC in Europe, overall and in males and females, 
are 29.5/100 000, 37.3/100 000 and 23.6/100 000, respectively.[1] 
The corresponding figures for sub-Saharan Africa are 5.8/100 000, 
6.4/100 000 and 5.4/100 000, respectively.[1] The incidence in this 
study falls in between that for developed countries and African 
statistics, possibly indicating that screening and surveillance of CRC 
are better than in developing countries but may not be as stringent as 
in developed countries.
Management and overall survival of CRC groups
CRC only
In our study, patients who received chemotherapy either before 
or after resection of the primary CRC appeared to have improved 
survival compared with those who underwent surgical resection 
only (Table 2). CRC treatment has been shown to be more effective 
when surgery is combined with chemotherapy.[9] The long survival 
of the chemotherapy-only group in this study is not in keeping with 
international series, and cannot be explained owing to the limited 
available clinical information such as accurate tumour staging.
CRCLM
Complete resection of CRCLM is the only treatment associated with 
long-term survival, with 37 - 54% 5YOS following surgical resection 
as opposed to 4 - 9% without surgical resection,[10] and potential cure 
in up to 16% of patients.[11]
In this series, 5YOS following resection of all disease was 57.3% if 
chemotherapy was administered before tumour resection, and 40.7% 
if surgery preceded chemotherapy (Table 2). Synchronous resection 
of the primary lesion as well as the liver metastases has been reported 
to have 40 - 47% 5YOS.[12] We were not able to determine 5YOS for 
synchronous resection in this study.
CRCLM resection is safe, with a mortality rate of <2% and a major 
morbidity rate of ~12.5%,[13,14] including patients aged >75 years, 
who can achieve 5YOS of 58%.[15] Patients may undergo repeated 
liver resections for recurrent CRCLM with similar survival figures to 
patients who only have one liver resection and no recurrence. One 
case series reported 47% 5YOS for repeat liver resection.[10] We were 
not able to perform survival analyses for repeated resections owing to 
the low numbers of these procedures.
CRCPM
Since the more widespread use of chemotherapy for pulmonary CRC 
metastases, overall survival has improved.[16] PM are typically single or 
multiple nodules, as opposed to a miliary type of spread or lymphangitis 
carcinomatosa, and hence more amenable to surgical resection.[17] 
5YOS following pulmonary metastectomy has been reported as 24 - 
61.4%,[18] and in this study was 31.5% (Table 2). The CRCPM resection 
mortality rate is <1% and the morbidity rate is ~14%.[19]
CRCLMPM
5YOS for patients with pulmonary metastectomy following hepatic 
metastectomy is 31.6%.[17] In this study, 5YOS was 26.0% (Table 2). 
Our figures also highlight the fact that relatively few patients undergo 
surgical resection of their metastatic disease. Median overall survival 
has been shown to be significantly improved with complete or 
macroscopically clear resection margins of CRCLMPM compared 
with palliative chemotherapy,[20] as well as resection of the primary 
CRC only in stage IV disease.[21]
Study limitations
There are limitations to this study. Data were retrieved from a single 
private healthcare funder’s database which represents 53% of the 
N=3 412
CRC only,
n=2 267 (66.4%)
Surgical treatment,
n=1 460 (64.4%)
Chemotherapy only,
n=432 (19.1%)
No treatment,
n=375 (16.5%)
Chemotherapy only, 
n=378 (33.0%)
No treatment,
n=80 (7.0%)
LM only, n=601 (52.5%)
PM only, n=182 (15.9%)
LM + PM, n=362 (31.6%)
CRC + LM/PM.
n=1 145 (33.6%)
CRC only, n=509 (44.4%)
LM, n=60 (10.0%)
PM, n=13 (7.1%)
LM + PM, n=10 (2.8%)
Surgical treatment*,
n=687 (60.0%)
Fig. 2. Disease presentation and management. (CRC = colorectal cancer; 
LM = liver metastases; PM = pulmonary metastases. *Patients may or may 
not have received chemotherapy.)
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Fig. 3. Overall survival of disease groups, regardless of treatment. (CRC = 
colorectal cancer; LM = liver metastases; PM = pulmonary metastases.)
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open market. This database is primarily designed for health economic 
data capture with limited clinical information. These results are based 
on treatments claimed from the medical scheme. Members may not 
necessarily submit all treatment claims to the scheme; for example, 
they may receive treatment as part of a clinical trial, use self-funded 
medication, or receive treatment from state facilities. Because of the 
paucity of clinical information, only general treatment patterns are 
reported. The survival estimates and Kaplan-Meier plot are limited by 
the fact that the analysed data do not originate from primary clinical 
data, but from secondary medical aid administrative and claims data. 
There may therefore be loss of accuracy and missing information. 
Furthermore, we could not adjust for covariates. However, we believe 
that the Kaplan-Meier plot remains the best way to display survival 
data, and we capped the estimates to 5 years, beyond which there are 
too few patients at risk for reliable estimates. We have provided 95% 
confidence intervals for these estimates.
Whether CRC in SA differs from internationally published series 
or whether patients are being managed appropriately cannot be 
determined from this study. Furthermore, our results cannot be 
extrapolated to the public healthcare sector, as the treatment of 
this disease appears to differ significantly with regard to disease 
presentation as well as access to chemotherapy and biological agents.
Future research
Appropriate clinical information should be collected by private 
healthcare funders to facilitate audit as well as to understand clinical 
decision-making and outcomes. The importance of multidisciplinary 
teams (MDTs) cannot be over-emphasised in the assessment of 
CRC with metastases to determine optimal patient management. 
A prospective study of an MDT showed that despite 84% of 
clinicians being certain of their management plan, following the 
MDT discussion 36% changed their management plan; 72% of these 
changes were major ones.[22] Furthermore, studies have shown lower 
survival rates following non-adherence to MDT decisions.[23] Finally, 
a national CRC registry should be established so that understanding 
of disease epidemiology, presentation, outcomes and therapeutic 
resources can be improved.
Conclusions
CRC patients treated in the SA private healthcare sector have 
improved survival following resection of the primary tumour 
and metastatic disease, which is further enhanced by the use of 
chemotherapy as opposed to chemotherapy alone or no treatment.
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